PE20151525A1 - Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado - Google Patents

Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado

Info

Publication number: PE20151525A1
Authority: PE; Peru
Prior art keywords: crenolanib; treatment; proliferative disorders; mutated flt3; flt3
Prior art date: 2013-01-07

Application number

PE2015001247A

Other languages

English (en)

Spanish (es)

Inventor

Vinay K Jain

Original Assignee

Arog Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-07

Filing date

2013-10-14

Publication date

2015-10-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061430&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151525(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-14 Application filed by Arog Pharmaceuticals Inc filed Critical Arog Pharmaceuticals Inc

2015-10-23 Publication of PE20151525A1 publication Critical patent/PE20151525A1/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Hematology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Hospice & Palliative Care (AREA)
Pathology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PE2015001247A 2013-01-07 2013-10-14 Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado PE20151525A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361749695P	2013-01-07	2013-01-07
US14/053,011 US9101624B2 (en)	2013-01-07	2013-10-14	Crenolanib for treating FLT3 mutated proliferative disorders

Publications (1)

Publication Number	Publication Date
PE20151525A1 true PE20151525A1 (es)	2015-10-23

Family

ID=51061430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2015001247A PE20151525A1 (es)	2013-01-07	2013-10-14	Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado

Country Status (31)

Country	Link
US (7)	US9101624B2 (fr)
EP (1)	EP2941251B1 (fr)
JP (1)	JP6288726B2 (fr)
KR (1)	KR101885952B1 (fr)
CN (4)	CN109966292A (fr)
AP (1)	AP2015008628A0 (fr)
AU (1)	AU2013371624B2 (fr)
BR (1)	BR112015016282A2 (fr)
CA (1)	CA2897445C (fr)
CL (1)	CL2015001923A1 (fr)
CY (1)	CY1120026T1 (fr)
DK (1)	DK2941251T3 (fr)
EA (1)	EA033910B1 (fr)
ES (1)	ES2667958T3 (fr)
HK (1)	HK1224211A1 (fr)
HR (1)	HRP20180478T1 (fr)
HU (1)	HUE038594T2 (fr)
IL (1)	IL239802B (fr)
LT (1)	LT2941251T (fr)
MX (1)	MX369137B (fr)
NO (1)	NO3019692T3 (fr)
NZ (1)	NZ710720A (fr)
PE (1)	PE20151525A1 (fr)
PH (1)	PH12015501531B1 (fr)
PL (1)	PL2941251T3 (fr)
PT (1)	PT2941251T (fr)
RS (1)	RS57076B1 (fr)
SG (2)	SG11201505327SA (fr)
SI (1)	SI2941251T1 (fr)
WO (1)	WO2014107209A2 (fr)
ZA (1)	ZA201505545B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101738063B1 (ko) *	2012-09-21	2017-05-19	아로그 파마슈티칼스, 인코퍼레이티드	구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
BR112015016282A2 (pt)	2013-01-07	2017-07-11	Arog Pharmaceuticals Inc	crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
JP6930991B2 (ja) *	2016-02-26	2021-09-01	セルジーンコーポレイション	血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤
EP3515559A4 (fr) *	2016-09-20	2020-07-15	Dana-Farber Cancer Institute, Inc.	Compositions et méthodes pour l'identification, l'évaluation, la prévention et le traitement de la lma au moyen de biomarqueurs usp10 et de modulateurs
KR20180074792A (ko)	2016-11-02	2018-07-03	아로그 파마슈티칼스, 인코퍼레이티드	돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙
EP3559006A4 (fr)	2016-12-23	2021-03-03	Arvinas Operations, Inc.	Composés et procédés pour la dégradation ciblée de polypeptides de kinase du foie f tal
CA3155215A1 (fr) *	2019-10-21	2021-04-29	Srikant Viswanadha	Compositions comprenant un inhibiteur dhodh pour le traitement de la leucemie myeloide aigue
WO2022019998A1 (fr) *	2020-07-20	2022-01-27	Arog Pharmaceuticals, Inc.	Formes cristallines de crénolanib et leurs procédés d'utilisation
US20220047574A1 (en) *	2020-08-15	2022-02-17	Arog Pharmaceuticals, Inc.	Crenolanib for treating pdgfr alpha mutated proliferative disorders
WO2022051429A1 (fr)	2020-09-02	2022-03-10	Daniel Choi	Systèmes et procédés pour environnements de réalité augmentée et jetons
US11969420B2 (en)	2020-10-30	2024-04-30	Arog Pharmaceuticals, Inc.	Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
JP2023063189A (ja) *	2021-10-22	2023-05-09	アログ・ファーマシューティカルズ・インコーポレイテッド	以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5990146A (en)	1997-08-20	1999-11-23	Warner-Lambert Company	Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
JP2001518470A (ja)	1997-09-26	2001-10-16	メルクエンドカムパニーインコーポレーテッド	新規な血管形成阻害剤
UA75055C2 (uk)	1999-11-30	2006-03-15	Пфайзер Продактс Інк.	Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
AU2002226877B2 (en)	2000-10-17	2006-01-12	Merck & Co., Inc.	Orally active salts with tyrosine kinase activity
DE60112956T2 (de) *	2000-10-31	2006-06-14	Ciba Sc Holding Ag	Kristalline formen von fluvastatin sodium
TWI238824B (en)	2001-05-14	2005-09-01	Novartis Ag	4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024969A1 (fr)	2001-09-14	2003-03-27	Merck & Co., Inc.	Inhibiteurs des tyrosine kinases
WO2003024931A1 (fr)	2001-09-14	2003-03-27	Merck & Co., Inc.	Inhibiteurs de tyrosine kinase
TWI259081B (en)	2001-10-26	2006-08-01	Sugen Inc	Treatment of acute myeloid leukemia with indolinone compounds
CN1582150B (zh)	2001-10-30	2011-09-07	诺瓦提斯公司	作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
CA2470480C (fr)	2001-12-27	2010-12-14	Theravance, Inc.	Derives d'indolinone utilises comme inhibiteurs de la proteine kinase
PE20040522A1 (es)	2002-05-29	2004-09-28	Novartis Ag	Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en)	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
CA2495386C (fr)	2002-08-14	2011-06-21	Vertex Pharmaceuticals Incorporated	Inhibiteurs de la proteine kinase et leurs utilisations
JP4613130B2 (ja)	2002-08-23	2011-01-12	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	ベンゾイミダゾールキノリノンおよびそれらの使用
PA8580301A1 (es)	2002-08-28	2005-05-24	Pfizer Prod Inc	Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
US20080207617A1 (en)	2002-10-29	2008-08-28	Kirin Beer Kabushiki Kaisha	Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
US7838527B2 (en)	2002-11-13	2010-11-23	Novartis Vaccines And Diagnostics, Inc.	Methods of treating cancer and related methods
AR042052A1 (es)	2002-11-15	2005-06-08	Vertex Pharma	Diaminotriazoles utiles como inhibidores de proteinquinasas
WO2004058749A1 (fr)	2002-12-18	2004-07-15	Vertex Pharmaceuticals Incorporated	Derives de benzisoxazole utiles en tant qu'inhibiteurs des proteine kinases
AU2004249511B2 (en)	2003-06-24	2011-01-20	Pfizer Products Inc.	Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
DE602006009539D1 (de) *	2005-10-28	2009-11-12	Irm Llc	Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
WO2012052757A1 (fr) *	2010-10-20	2012-04-26	Astrazeneca Ab	Procédé de sélection de patients selon leur phénotype tumoral
EP2785355A4 (fr) *	2011-11-30	2015-12-02	Cedars Sinai Medical Center	Ciblage des microarn mir-409-5p, mir-379 et mir-154* pour traiter la métastase osseuse du cancer de la prostate et le cancer du poumon résistant aux médicaments
KR101738063B1 (ko)	2012-09-21	2017-05-19	아로그 파마슈티칼스, 인코퍼레이티드	구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
TWI599356B (zh)	2012-09-26	2017-09-21	安羅格製藥有限責任公司	抑制突變型ｃ－ｋｉｔ的方法
BR112015016282A2 (pt)	2013-01-07	2017-07-11	Arog Pharmaceuticals Inc	crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado

2013
- 2013-07-10 BR BR112015016282A patent/BR112015016282A2/pt not_active Application Discontinuation
- 2013-10-14 DK DK13869984.8T patent/DK2941251T3/en active
- 2013-10-14 AU AU2013371624A patent/AU2013371624B2/en active Active
- 2013-10-14 CN CN201910222133.6A patent/CN109966292A/zh active Pending
- 2013-10-14 EP EP13869984.8A patent/EP2941251B1/fr active Active
- 2013-10-14 EA EA201591290A patent/EA033910B1/ru unknown
- 2013-10-14 CA CA2897445A patent/CA2897445C/fr active Active
- 2013-10-14 JP JP2015551670A patent/JP6288726B2/ja active Active
- 2013-10-14 LT LTEP13869984.8T patent/LT2941251T/lt unknown
- 2013-10-14 NZ NZ710720A patent/NZ710720A/en unknown
- 2013-10-14 ES ES13869984.8T patent/ES2667958T3/es active Active
- 2013-10-14 SG SG11201505327SA patent/SG11201505327SA/en unknown
- 2013-10-14 PE PE2015001247A patent/PE20151525A1/es not_active Application Discontinuation
- 2013-10-14 CN CN201380069700.XA patent/CN105555272A/zh active Pending
- 2013-10-14 AP AP2015008628A patent/AP2015008628A0/xx unknown
- 2013-10-14 KR KR1020157021078A patent/KR101885952B1/ko active IP Right Grant
- 2013-10-14 HU HUE13869984A patent/HUE038594T2/hu unknown
- 2013-10-14 PT PT138699848T patent/PT2941251T/pt unknown
- 2013-10-14 US US14/053,011 patent/US9101624B2/en active Active
- 2013-10-14 SG SG10201705611PA patent/SG10201705611PA/en unknown
- 2013-10-14 RS RS20180287A patent/RS57076B1/sr unknown
- 2013-10-14 WO PCT/US2013/064821 patent/WO2014107209A2/fr active Application Filing
- 2013-10-14 CN CN202011110066.8A patent/CN112138010A/zh active Pending
- 2013-10-14 SI SI201330974T patent/SI2941251T1/en unknown
- 2013-10-14 PL PL13869984T patent/PL2941251T3/pl unknown
- 2013-10-14 MX MX2015008777A patent/MX369137B/es active IP Right Grant
- 2013-10-14 CN CN201910222143.XA patent/CN110200970A/zh active Pending
2014
- 2014-07-03 NO NO14742440A patent/NO3019692T3/no unknown
2015
- 2015-05-04 US US14/703,500 patent/US9393240B2/en active Active
- 2015-07-06 IL IL239802A patent/IL239802B/en active IP Right Grant
- 2015-07-07 PH PH12015501531A patent/PH12015501531B1/en unknown
- 2015-07-07 CL CL2015001923A patent/CL2015001923A1/es unknown
- 2015-07-31 ZA ZA2015/05545A patent/ZA201505545B/en unknown
2016
- 2016-06-28 US US15/195,297 patent/US9801870B2/en active Active
- 2016-11-02 HK HK16112610.7A patent/HK1224211A1/zh unknown
2017
- 2017-09-26 US US15/715,274 patent/US10213423B2/en active Active
2018
- 2018-03-12 CY CY20181100293T patent/CY1120026T1/el unknown
- 2018-03-22 HR HRP20180478TT patent/HRP20180478T1/hr unknown
2019
- 2019-02-22 US US16/282,716 patent/US11007188B2/en active Active
2020
- 2020-08-18 US US16/996,400 patent/US11458131B2/en active Active
2022
- 2022-08-30 US US17/898,632 patent/US20220409610A1/en active Pending

Also Published As

Publication number	Publication date
SG11201505327SA (en)	2015-08-28
US20180015081A1 (en)	2018-01-18
EP2941251A2 (fr)	2015-11-11
JP2016508148A (ja)	2016-03-17
HRP20180478T1 (hr)	2018-06-15
AP2015008628A0 (en)	2015-08-31
BR112015016282A2 (pt)	2017-07-11
US20150238479A1 (en)	2015-08-27
CA2897445A1 (fr)	2014-07-10
RS57076B1 (sr)	2018-06-29
US20160303109A1 (en)	2016-10-20
DK2941251T3 (en)	2018-03-26
NZ710720A (en)	2020-06-26
IL239802A0 (en)	2015-08-31
AU2013371624A1 (en)	2015-08-20
SI2941251T1 (en)	2018-06-29
CN112138010A (zh)	2020-12-29
AU2013371624B2 (en)	2018-02-08
US20140194464A1 (en)	2014-07-10
MX369137B (es)	2019-10-30
HK1224211A1 (zh)	2017-08-18
ES2667958T3 (es)	2018-05-16
IL239802B (en)	2020-06-30
NO3019692T3 (fr)	2018-06-16
LT2941251T (lt)	2018-04-10
PH12015501531A1 (en)	2015-09-21
US11007188B2 (en)	2021-05-18
US9801870B2 (en)	2017-10-31
US11458131B2 (en)	2022-10-04
EA033910B1 (ru)	2019-12-09
HUE038594T2 (hu)	2018-10-29
PT2941251T (pt)	2018-03-23
CL2015001923A1 (es)	2016-01-15
ZA201505545B (en)	2016-10-26
EA201591290A3 (ru)	2016-07-29
PL2941251T3 (pl)	2018-07-31
SG10201705611PA (en)	2017-08-30
EA201591290A2 (ru)	2016-03-31
US20220409610A1 (en)	2022-12-29
US20190183879A1 (en)	2019-06-20
US20200390756A1 (en)	2020-12-17
PH12015501531B1 (en)	2015-09-21
CN105555272A (zh)	2016-05-04
MX2015008777A (es)	2015-11-13
US9101624B2 (en)	2015-08-11
CN110200970A (zh)	2019-09-06
CA2897445C (fr)	2019-04-30
EP2941251A4 (fr)	2016-08-24
US9393240B2 (en)	2016-07-19
JP6288726B2 (ja)	2018-03-07
US10213423B2 (en)	2019-02-26
CY1120026T1 (el)	2018-12-12
KR20150141930A (ko)	2015-12-21
WO2014107209A2 (fr)	2014-07-10
EP2941251B1 (fr)	2018-03-07
CN109966292A (zh)	2019-07-05
KR101885952B1 (ko)	2018-08-06

Legal Events

Date	Code	Title	Description
2018-10-12	FA	Abandonment or withdrawal

Publication	Publication Date	Title
PE20151525A1 (es)	2015-10-23	Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado
PH12019501197A1 (en)	2020-08-24	Therapeutically active compounds and their methods of use
IL268094B (en)	2020-07-30	History of heterocyclic compounds for use in the treatment of lung cancer
IL304851A (en)	2023-09-01	Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
PH12017501419B1 (en)	2018-10-08	Therapeutically active compounds and their methods of use
IL242881B (en)	2019-09-26	A toxic substance for use in combination with radiation in cancer treatment
MY172578A (en)	2019-12-03	Oral dosing of glp-1 compounds
MX356698B (es)	2018-06-11	Compuestos de tubulisina, metodos para obtenerlos y uso.
BR112016002287A2 (pt)	2017-08-01	compostos terapeuticamente ativos e seus métodos de uso
MX2016004678A (es)	2017-03-10	Composiciones para el tratamiento del cancer.
MX350432B (es)	2017-09-06	Compuestos terapeuticamente activos y sus metodos de empleo.
GB2495841B (en)	2016-02-10	Phytocannabinoids for use in the treatment of breast cancer
MX2016007311A (es)	2016-09-07	Metodos para tratar canceres.
IL239007B (en)	2018-04-30	Eribulin for use in the treatment of breast cancer
UY32987A (es)	2011-05-31	Nuevo uso antitumoral de cabazitaxel
IL276423B2 (en)	2024-05-01	Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment
SV2015005126A (es)	2017-01-30	Nuevos compuestos para el tratamiento del cáncer
IL245164A0 (en)	2016-06-30	A biodegradable preparation containing antibacterial substances and its use for the treatment of lower back pain
EP3003489A4 (fr)	2017-02-08	Agents cytotoxiques destinés au traitement du cancer
EA201200190A1 (ru)	2012-08-30	Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы
PL3071192T3 (pl)	2020-06-29	Związek kurkufenol do zastosowania w leczeniu nowotworu
IL246065A0 (en)	2016-07-31	Valiprib in combination with carboplatin for the treatment of triple negative breast cancer
IN2015KN00676A (fr)	2015-07-17
HK1202453A1 (en)	2015-10-02	Therapeutic composition for treating cancers
EP3104863C0 (fr)	2023-10-18	Salicylates pour l'utilisation dans le traitement du cancer